

## DAFTAR PUSTAKA

- Abal, M., Andreu, J.M., Barasoain I., Taxanes, 2003, Microtubule and centrosome targets, and cell cycle dependent mechanisms of action, *Current Cancer Drug Targets*, 3:193203.
- Acharya, G., Park, K., 2006, Mechanisms of controlled drug release from drug-eluting stents, *Adv. Drug Deliv. Rev.*, 58:387–401.
- AL-Mangour B, Mongrain R, Yue S., 2013, Coronary stents fracture: an engineering approach (review). *Mater Sci Appl.*, 4(10):606–21.
- Bellefontaine, G., 2010, *The Corrosion of CoCrMo Alloys for Biomedical Applications*, [Thesis], School of Metallurgy and Materials, University of Birmingham.
- Bognár, E., György, R., Balázs, T., Dobránszky, J., 2008, Investigation of Drug Eluting Stents, *Materials Science Forum*, 589 : 361-366.
- Buellesfeld, L., Grube, E., 2004, ABT-578-eluting stents-the promising successor of sirolimus and paclitaxel-eluting stent concepts, *Herz*, 29:167–170.
- Carter, A.J., Brodeur, A., Collingwood, R., Ross, S., *et al.*, 2006, Experimental efficacy of an everolimus eluting cobalt chromium stent, *Catheter. Cardiovasc. Interv.*, 68:97–103.
- Chen W., Habraken T. C. J., Hennink W. E., and Kok R. J. 2015. Polymer-Free Drug-Eluting Stents: An Overview of Coating Strategies and Comparison with Polymer-Coated Drug-Eluting Stents. *Bioconjugate Chemistry*, 26 (7), 1277-1288.
- Chen, H.W., Huang, H.C., 1998, Effect of curcumin on cell cycle progression and apoptosis in vascular smooth muscle cells, *Br J Pharmacol.*, 124(6):1029-40.
- Chevalier B., Serruys P.W., Silber S., Garcia E., *et al.*, 2007, Randomised comparison of nobori, biolimus a9-eluting coronary stent with ataxus®, paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: The nobori 1 trial, *EuroIntervention*, 2: 426434.
- Clarke S.J., Rivory L.P., 1999, Clinical pharmacokinetics of docetaxel. *Clinical Pharmacokinetics*, 36: 99-114.

- Cumashi, A., Ushakova, N.A., Preobrazhenskaya, M.E., *et al.*, 2007, A comparative study of the anti-inflammatory, anticoagulant, antiangiogenic, and antiadhesive activities of nine different fucoidans from brown seaweeds, *Glycobiology*, 17:541–552.
- Dasnurkar, A.C., 2006, Drug Loaded Polymeric Blends For Developing Vascular Stents, [Thesis], The University of Texas at Arlington.
- de la Lastra C., Villegas I., 2007, Resveratrol as an antioxidant and pro-oxidant agent: Mechanisms and clinical implications, *Biochemical Society Transactions*, 35:11561160.
- Dentaurum, 2011, remanium® star CL material data sheet, [internet] diunduh pada 17 Juli 2019, Tersedia pada: <https://www.dentaurum.de/eng/cocr-legierung-remanium-star-cl-23836.aspx>
- Dinarvand, R., Mahmoodi, S., Farboud, E., Salehi, M., Atyabi, F., 2005, Preparation of gelatin microspheres containing lactic acid—effect of crosslinking on drug release, *Acta Pharmaceutica*, 55 : 57–67.
- Dunn C., Croom K.F., 2006, Everolimus: A review of Its use in renal and cardiac transplantation, *Drugs*, 66:547-570.
- Fajadet J., Wijns W., Laarman G.J., Kuck K.H., *et al.*, 2006, Randomized, double-blind, multicenter study of the endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: Clinical and angiographic results of the endeavour ii trial, *Circulation*, 114:798-806.
- Farb, A., Kolodgie, F.D., Hwang, J.Y., 2004, Extracellular matrix changes in stented human coronary arteries, *Circulation*, 110:940–947.
- Finn, A.V., Kolodgie, F.D., Harnek, J., Guerrero, L.J., Acampado, E., Tefera, K., Skorija, K., Weber, D.K., Gold, H.K., Virmani, R., 2005, Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus or paclitaxel-eluting stents, *Circulation*, 112:270–278.
- Fogarotto, F., 2011, *Finite Element Analysis of Coronary Artery Stenting*, [Thesis], Università degli Studi di Pavia, Italia.
- Guha M., Mackman N., 2002, The phosphatidylinositol 3-kinase-akt pathway limits lipopolysaccharide activation of signaling pathways and expression of inflammatory mediators in human monocytic cells, *Journal of Biological Chemistry*, 277:32124-32132.

- Gocke, C., N. Grabow, C. Schultze, K. Sternberg, W. Schmidt, K.-P. Schmitz, 2010, Coating homogeneity in the manufacture of Drug-Eluting Stents, *IFMBE Proceedings*, 22 : 2240-2243
- Gunatillake P.A., Adhikari R., 2003, Biodegradable synthetic polymers for tissue engineering, *Eur Cells Mat*, 5:1-16.
- Gupta A.K., Chow M., 2003, Pimecrolimus: A review. *Journal of the European Academy of Dermatology & Venereology*, 17:493-503.
- Halloran P.F., 2004, Immunosuppressive drugs for kidney transplantation. *New England Journal of Medicine*, 351:2715-2729.
- Holmes, D.R.Jr., Kereiakes, D.J., Garg S., 2010, Stent thrombosis. *J Am Coll Cardiol*, 56:1357-65.
- Kemendes RI (2013) *Riset Kesehatan Dasar*. Jakarta
- Kharaziha, M., Fathi, M. H., Edris, H., Nourbakhsh, N., Talebi, A., dan Salmanzadeh, S., 2015, PCL-forsterite nanocomposite fibrous membranes for controlled release of dexamethasone, *Journal of Materials Science: Materials in Medicine*, 26(1) : 36.
- Koudi, M.S., Patil, S.B., 2007, Prep Manual for Undergraduates. Dental Materials. Elsevier, New Delhi.
- Lasave L.I., Costa Jd.R., Abizaid A.A., Feres F., *et al.*, 2007, A three-dimensional intravascular ultrasound comparison between the new zotarolimus-eluting stent (zomaxx™) and the nondrug-eluting trimaxx™ stent, *Journal of Invasive Cardiology*, 19:303-308.
- Lee, C.H., Kim, J.H., 2014, A review on the medicinal potentials of ginseng and ginsenosides on cardiovascular diseases. *J. Ginseng Res*, 38:161–6.
- Lisawati, 2007, *Biokompatibilitas Titanium dalam Penggunaannya di Kedokteran Gigi*, [Skripsi], Fakultas Kedokteran Gigi Universitas Sumatera Utara.
- Logeart, S., Prigent-Richard, J., Jozefonvicz, D., Letourneur, 1997, Fucans, sulphated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. I. Comparison with heparin for antiproliferative activity, binding and internalization, *Eur. J. Cell Biol*, 74:376–384.
- Michelsen K.S., Wong M.H., Shah P.K., Zhang W., *et al.*, 2004, Lack of Toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein, *E. Proc Natl Acad Sci USA*, 101:10679–84.

- Mohammadi F, Golafshan N, Kharaziha M, Ashrafi A, 2019, Chitosan-heparin nanoparticle coating on anodized NiTi for improvement of blood compatibility and biocompatibility, *International Journal of Biological Macromolecules*, <https://doi.org/10.1016/j.ijbiomac.2019.01.026>
- Mohanty, C. dan Sahoo, S.K., 2010, The in vitro stability and in vivo pharmacokinetics of curcumin prepared as an aqueous nanoparticulate formulation, *Biomaterial*. 31:6597-6611.
- Moses J.W., Leon M.B., Popma J.J., Fitzgerald P.J., *et al.*, 2003, Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. *N. Engl. J. Med.*, 349:1315-1323.
- Nag, S.A., Qin, J.J., Wang, W., Wang, M.H., Wang, H., Zhang, R., 2012, Ginsenosides as anticancer agents: In vitro and in vivo activities, structure-activity relationships, and molecular mechanisms of action. *Front, Pharmacol*, 3:1–18.
- Nainggolan, B.M.H., 2009, Perbandingan Uji Tukey (Uji Beda Nyata Jujur (BNJ)) dengan Uji Fisher (Uji Beda Nyata Terkecil (BNT)) dalam Uji Lanjut Data Rancangan Percobaan, *Majalah Ilmiah Panorama Nusantara*, edisi VII
- Nakazawa, G., 2011, Stent thrombosis of drug eluting stent: pathological perspective, *J.Cardiol*, 58: 84–91.
- Nasruddin, 2005, *Dynamic Modeling and Stimulation of a Two-Bed Silicagel-Water Adsorption Chiller*, Disertasi, Rwth Aachen, hal. 3-12
- NhISO, 2018, *Biological Evaluation of Medical Devices – Part 18 Part 19 First Edition*, IHS, Switzerland
- ISO, 2006, *Biological Evaluation of Medical Devices –Part 19 First Edition*, IHS, Switzerland
- Olas B., Wachowicz B., 2005, Resveratrol, a phenolic antioxidant with effects on blood platelet functions, *Platelets*, 16:251-260.
- Pan, Ch. J., Tang, J.J., Weng, Y.J., Wang, J., Huang, N., 2006, Preparation, characterization and anticoagulation of curcumin-eluting controlled biodegradable coating stents, *Journal of Controlled Release*, 116:42–49.
- Patel J.K., Kobashigawa J.A., 2006, Everolimus: An immunosuppressive agent in transplantation. *Expert opinion on pharmacotherapy*, 7:1347-1355.

- Poussier B., Cordova A.C., Becquemin J.P., Sumpio B.E., 2005, Resveratrol inhibits vascular smooth muscle cell proliferation and induces apoptosis. *Journal of Vascular Surgery*, 42:1190-1197.
- Puranik, A.S., Dawson, E.R., Peppas, N.A., 2013, Recent advances in drug eluting stents, *International Journal of Pharmaceutics*, 441:665– 679.
- Rachmawati, H., Y.L. Yanda, A. Rahma, N. Mase, 2016, Curcumin-Loaded PLA Nanoparticles: Formulation and Physical Evaluation, *Scientia Pharmaceutica*, 84: 191–202
- Raharjo, S., 2016, *Cara Uji Paired Sample T-Test dan Interpretasi dengan SPSS*, [Internet], diunduh pada 10 Juli 2018, Tersedia pada : <https://www.spssindonesia.com/2016/08/cara-uji-paired-sample-t-test-dan.html>
- Raharjo, S., 2017, *Cara Melakukan Analisis Anova Satu Faktor dengan SPSS*, [Internet], diunduh pada 21 November 2019, Tersedia pada : <https://www.spssindonesia.com/2017/10/analisis-anova-satu-faktor-spss.html>
- Reddy, T.R.K., dan H.J., Kim, 2018, Mechanical, Optical, Thermal, and Barrier Properties of Poly (Lactic Acid)/Curcumin Composite Films Prepared Using Twin-Screw Extruder, *Food Biophysics*, 14:22–29
- Riskawati, D.N., 2010, *Pengukuran Tingkat Kekasaran Permukaan Benda Menggunakan Metode Time-Of-Flight Gelombang Ultrasonik*, [Skripsi], Jurusan Fisika FMIPA Universitas Diponegoro, Semarang.
- Rogers, C.D.K., 2005, Drug-eluting stents: clinical perspectives on drug and design differences, *Rev. Cardiovasc. Med.* 6:S3–S12.
- Santoso S., 2016, Mengenal Teknik Modern Dalam Pengobatan Penyakit Jantung Koroner: Kateterisasi dan Tindakan Pelebaran Kembali Penyempitan Pembuluh Darah Jantung, [Internet] diunduh pada 20 November 2018, Tersedia pada: [https://www.medistra.com/index.php?option=com-content&view=article&id=107:Mengenal%20DES%20\(Drug-Eluting%20Stent\)&catid=39:Info%20Kesehatan%20Rs.%20Medistra](https://www.medistra.com/index.php?option=com-content&view=article&id=107:Mengenal%20DES%20(Drug-Eluting%20Stent)&catid=39:Info%20Kesehatan%20Rs.%20Medistra).
- Satya, B., 2009, Pengaruh waktu perendaman resin pit fissure sealant pada medium kultur terhadap viabilitas sel HaCaT (in vitro), [Skripsi], Universitas Indonesia
- Shaikh M., Kichenadasse G., Choudhury N. R., Butler R., and Garg S. 2013. Non-vascular Drug Eluting Stents as Localized Controlled Drug Delivery Platform: Preclinical and Clinical Experience. *J Control Release* 172: 105-117.

- Shishodia, S., Sethi, G., Aggarwal, B.B., 2005, Curcumin: Getting Back to the Roots. *Ann. N.Y. Acad.Sci*, 1056:206-217.
- So Hee N., Hye Yeong N., Jae Ryang J., In Su B., dan Jong-Sang P., 2007, Curcumin-Loaded PLGA Nanoparticles Coating onto Metal Stent by EPD, *Bull. Korean Chem. Soc.*,28(3):397-402
- Sousa, J. E., Serruys, P. W., Costa, M. A., 2003, New frontiers in cardiology, drug-eluting stents: part I, *Circulation*, 107 : 2274–2279.
- Stahli B.E., Camici G.G., Steffel J., Akhmedov A., Shojaati K., *et al.*, 2006, Paclitaxel enhances thrombin-induced endothelial tissue factor expression via c-jun terminal nh2 kinase activation. *Circulation Research*, 99:149-155.
- Steffel J., Luscher T.F., Tanner F.C., 2006, Tissue factor in cardiovascular diseases molecular mechanisms and clinical implications. *Circulation*, 113:722-731.
- Sternberg K., S. Kramer, C. Nischan, N. Grabow, T. Langer, G. Hennighausen, 2007, In vitro study of drug-eluting stent coatings based on poly(l-lactide) incorporating cyclosporine A–drug release, polymer degradation and mechanical integrity, *Journal of Materials Science: Materials in Medicine*, 18:1423.
- Stone G.W., Ellis S.G., Cannon L., Mann J.T., *et al.*, 2005, Comparison of a polymer-based paclitaxel-eluting stent with a bare metal stent in patients with complex coronary artery disease: A randomized controlled trial, *JAMA*, 294:1215-1223.
- Stone G.W., Midei M., Newman W., Sanz M., Hermiller J.B., Williams J., Farhat N., Mahaffey K.W., Cutlip D.E., Fitzgerald P.J., Sood P., Su X., Lansky A.J., 2008, Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: A randomized trial, *JAMA*, 299:1903-1913.
- Sujatno, A., R. Salam, Bandriyana, A. Dimiyati, 2015, Studi Scanning Electron Microscopy (SEM) untuk Karakterisasi Proses Oksidasi Paduan Zirkonium, *Jurnal Forum Nuklir (JFN)*, 9 (2) : 44-50
- Sun, Y., Liu, Y., Chen, K., 2016, Roles and mechanisms of ginsenoside in cardiovascular diseases: progress and perspectives, *Sci. China Life Sc*, 59:292-298.
- Sun J., Marx S.O., Chen H.J., Poon M., Marks A.R., Rabbani L.R.E., 2001, Role for p27kip1 in vascular smooth muscle cell migration, *Circulation*, 103:2967-2972.

- Tanimoto, S., Serruys, P.W., Thuesen, L., Dudek, D., de Bruyne, B., Chevalier, B., Ormiston, J.A., 2007, Comparison of in vivo acute stent recoil between the bioabsorbable everolimus-eluting coronary stent and the everolimus-eluting cobalt chromium coronary stent: insights from the ABSORB and SPIRIT trials, *Catheter.Cardiovasc.Interv.*, 70:515–523.
- Trijono, R., 2015, *Metodologi Penelitian Kuantitatif*, Papas Sinar Sinanti, Depok Timur, Indonesia
- Virmani R., Liistro F., Stankovic G., *et al.*, 2002, Mechanism Of Late In-Stent Restenosis After Implantation Of A Paclitaxel Derivate-Eluting Stent System In Humans, *Circulation*, 106:2649–2651.
- Waksman R., Pakala R., Baffour R., Hellinga D., Seabron R., Kolodgie F., Virmani R., 2006, Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries, *Cardiovascular Revascularization Medicine*, 7:179184.
- Wilson, G.J., Nakazawa, G., Schwartz, R.S., Huibregtse, B., Poff, B., Herbst, T.J., Baim, D.S., Virmani, R., 2009, Comparison of inflammatory response after implantation of sirolimus- and paclitaxel-eluting stents in porcine coronary arteries, *Circulation*, 120:U141–U175.
- Zhan, X., X. Guo, R. Liu, W. Hu, L. Zhang, N. Xiang, 2017, Intervention using a novel biodegradable hollow stent containing polylactic acid-polyprolactone-polyethylene glycol complexes against lacrimal duct obstruction disease, *PLoS ONE*, 12(6): e0178679